Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer’s Disease
NEW YORK, March 17, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the publication of an article titled, The Clinical Promise of Biomarkers of Synapse Damage or Loss in Alzheimer’s Disease, which reviews the […]